Valuation: Matricelf Ltd

Market Cap 73.35M 0 24.54M 21.02M 19.67M 18M 33.79M 2.35B 34.23M 232M 90.61M 1.18B 92.14M 90.13M 3.9B P/E 2024
-3.74x
P/E 2025 -3.65x
Enterprise Value 53.21M 0 17.8M 15.25M 14.27M 13.06M 24.51M 1.7B 24.83M 169M 65.73M 856M 66.84M 65.38M 2.83B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.85%
Yield 2024 *
-
Yield 2025 -
1 day+1.75%
1 week-4.10%
Current month+2.82%
1 month+2.37%
3 months-4.60%
6 months-49.22%
Current year-53.68%
1 week 245
Extreme 245
280
1 month 231
Extreme 231
309.8
Current year 212
Extreme 212
853
1 year 212
Extreme 212
853
3 years 204
Extreme 204
853
5 years 204
Extreme 204
1,555
10 years 204
Extreme 204
1,555
Manager TitleAgeSince
Chief Executive Officer 54 2019-05-31
Chief Tech/Sci/R&D Officer 51 2019-05-31
Chief Operating Officer 59 2019-06-30
Director TitleAgeSince
Director/Board Member 59 2019-06-30
Director/Board Member 51 2019-05-31
Director/Board Member 68 2022-07-26
Change 5-day change 1-year change 3-year change Capi.($)
+1.75%-4.10%-20.37%-44.10% 24.54M
-1.18%+3.64%+2.48%+22.93% 51.61B
-0.87%-2.64%+478.64%+548.65% 44.89B
+0.02%+7.92%+38.46%+20.80% 42.77B
-1.41%+1.08%+18.73%+84.25% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
-0.33%+3.61%+32.54%+144.71% 17.33B
-1.21%+0.49% - - 16.63B
+0.69%+4.77%+9.89%+31.01% 14.76B
+0.06%+3.01%+79.93%+48.67% 14.09B
Average -0.34%+3.26%+72.94%+101.42% 27.65B
Weighted average by Cap. -0.74%+4.72%+101.62%+137.45%

Financials

2024 2025
Net sales - -
Net income -15.58M -0 -5.21M -4.47M -4.18M -3.82M -7.18M -499M -7.27M -49.36M -19.25M -251M -19.57M -19.15M -829M -27.82M -0 -9.31M -7.97M -7.46M -6.83M -12.82M -891M -12.98M -88.14M -34.37M -447M -34.95M -34.19M -1.48B
Net Debt -10.68M -0 -3.57M -3.06M -2.86M -2.62M -4.92M -342M -4.98M -33.83M -13.19M -172M -13.42M -13.12M -568M -20.14M -0 -6.74M -5.77M -5.4M -4.94M -9.28M -645M -9.4M -63.8M -24.88M -324M -25.3M -24.75M -1.07B
Logo Matricelf Ltd
Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
Employees
-
Date Price Change Volume
26-08-24 ILA 255.20 +1.75% 58,275
26-08-21 ILA 250.80 -2.26% 63,759
26-08-20 ILA 256.60 -2.28% 54,910
26-08-19 ILA 262.60 -0.30% 73,464
26-08-18 ILA 263.40 -1.01% 153,965
  1. Stock Market
  2. Stocks
  3. MTLF Stock